» Authors » Dimitrios Karantanis

Dimitrios Karantanis

Explore the profile of Dimitrios Karantanis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 227
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Vassilakopoulos T, Piperidou A, Mellios Z, Verigou E, Katodritou E, Kalpadakis C, et al.
Hemasphere . 2023 Nov; 7(11):e965. PMID: 38027423
No abstract available.
2.
Kalkanis A, Palaiodimos L, Klinaki I, Karantanis D, Kalkanis D
Nucl Med Mol Imaging . 2017 Sep; 51(3):277-280. PMID: 28878858
A 63-year-old male with a recently diagnosed right lung lesion was referred for staging. F-FDG PET/CT scan revealed a hypodense, cystic-like mass in the right upper lung lobe, which demonstrated...
3.
Karantanis D, Kalkanis D, Czernin J, Herrmann K, Pomykala K, Bogsrud T, et al.
J Nucl Med . 2014 Dec; 55(12):1925-9. PMID: 25453041
Unlabelled: Because only pathologic examination can confirm the presence or absence of malignant disease in cancer patients, a certain rate of misinterpretation in any kind of imaging study is inevitable....
4.
Dibble E, Karantanis D, Mercier G, Peller P, Kachnic L, Subramaniam R
AJR Am J Roentgenol . 2012 Oct; 199(5):952-67. PMID: 23096166
Objective: Pancreatic cancer continues to have a poor prognosis despite impressive improvements in the outcomes of many other types of cancer, often because most pancreatic neoplasms are found to be...
5.
Karantanis D, Kalkanis D, Allen-Auerbach M, Bogsrud T, Subramaniam R, Danielson A, et al.
J Nucl Med . 2012 Aug; 53(10):1499-505. PMID: 22917886
Unlabelled: Oncologic (18)F-FDG PET/CT is rapidly gaining acceptance in clinical practice. However, the referring physician's attitude toward the usefulness of this diagnostic modality is unknown. This survey was undertaken to...
6.
Karantanis D, Allen-Auerbach M, Czernin J
Clin Nucl Med . 2012 Apr; 37(5):e98-9. PMID: 22475925
Squamous papilloma is one of the most common benign neoplasms of the oral cavity and oropharynx. The (18)F-FDG PET/CT metabolic phenotype of this entity has not been described. We document...
7.
Karantanis D, Allen-Auerbach M, Czernin J
Hell J Nucl Med . 2012 Mar; 15(1):2-8. PMID: 22413105
Positron emission tomography (PET)/computed tomography (CT)-subsequently referred to as PET/CT is emerging as a critically important diagnostic tool in oncology. There has been a substantial increase in the utilization of...
8.
Karantanis D, Allen-Auerbach M, Czernin J
Clin Nucl Med . 2011 Dec; 37(1):49-53. PMID: 22157028
Purpose: Knowing the glycolytic phenotype of cancers is important for the appropriate use of F-18 FDG PET/CT imaging. This study was performed to determine the influence of tumor grade and...
9.
Bogsrud T, Hay I, Karantanis D, Nathan M, Mullan B, Wiseman G, et al.
Nucl Med Commun . 2011 Feb; 32(4):245-51. PMID: 21278616
Objective: To explore the prognostic value of F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in radioiodine-negative patients with differentiated follicular cell-derived thyroid carcinoma with circulating antithyroglobulin autoantibodies (TgAb). Methods: We retrospectively reviewed...
10.
Bogsrud T, Karantanis D, Nathan M, Mullan B, Wiseman G, Kasperbauer J, et al.
Mol Imaging Biol . 2009 Dec; 12(5):547-53. PMID: 19949985
Purpose: To explore the prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography (PET) in patients with suspected residual or recurrent medullary thyroid carcinoma (MTC). Procedures: This retrospective study included all...